Healthcare
Live Price
Offline$23.20
+0.00% today
1Y Change
-17.58%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 251 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tsumura & Co. (TSMRF) is a Healthcare stock with a market cap of $270.60B and listed on OTC. The stock last traded around $23.20 and down 17.6% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +20.1%, EPS growth of +94.3%, a dividend yield of 4.0%. What stands out right now is revenue +20.1%, EPS +94.3%, free cash flow +127.9% with operating margin 19.3% and ROIC 5.6%. The dividend matters to the case here, with a current yield around 4.0%. Valuation is more restrained than many high-expectation growth names at P/E 9.3 and price/sales 1.4. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines TSMRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TSMRF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TSMRF Max Drawdown
-17.58%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TSMRF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$116.4B
-10.1% YoY
FY Net Income
$15.3B
-18.6% YoY
Free Cash Flow
$6.7B
-37.7% YoY
Revenue Growth
+20.1%
EPS Growth
+94.3%
Gross Margin
47.6%
Net Margin
15.3%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 181.1B | 150.8B | 140.0B | 129.5B | 116.4B |
| Gross Profit | 90.6B | 68.8B | 68.3B | 66.5B | 60.5B |
| Operating Income | 40.1B | 20.0B | 20.9B | 22.4B | 19.4B |
| EBITDA | 57.2B | 34.8B | 33.9B | 31.6B | 28.0B |
| Net Income | 32.4B | 16.7B | 16.5B | 18.8B | 15.3B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 73.2B | 78.1B | 94.8B | 67.6B | 61.3B |
| Total Assets | 464.4B | 428.3B | 396.8B | 351.0B | 319.1B |
| Total Liabilities | 134.3B | 132.9B | 124.6B | 92.9B | 85.9B |
| Shareholder Equity | 300.5B | 270.8B | 252.0B | 239.8B | 217.8B |
| Total Debt | 70.3B | 79.7B | 79.7B | 49.7B | 52.9B |
| Net Debt | -2.9B | 1.6B | -15.1B | -17.9B | -8.5B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
16.1B
-24.5% YoY
Capital Expenditures
9.4B
+11.1% YoY
Free Cash Flow
6.7B
-37.7% YoY
Key ratios
Gross Margin
47.6%
Operating Margin
19.3%
Net Margin
15.3%
ROE
9.8%
Debt / Equity
0.44x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.